Effect of a Low Starch Diet in Patients With Ankylosing Spondylitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04386538|
Recruitment Status : Not yet recruiting
First Posted : May 13, 2020
Last Update Posted : May 15, 2020
|Condition or disease||Intervention/treatment||Phase|
|Spondyloarthritis Ankylosing Spondylitis||Behavioral: Low Starch Diet (LSD) Behavioral: General healthy eating||Not Applicable|
Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease characterized by axial inflammation and with unknown aetiology. The immune system dysregulation is known, where genetic factors play a key role, in particular, the susceptibility associated to the HLA-B27 allele. The presence of this genetic marker, seems to trigger an abnormal response of the individual, under the action of determine microorganisms, and probably, the combination of these two factors may contribute to the manifestation of the disease, through the induction of an immune and cytolytic response, leading to tissue injury and promoting the inflammation. Intestinal microbiota involvement in spondylarthritis is a controversial issue, however, was observed an increased concentration of Klebsiella pneumoniae bacteria in the faeces of AS patients. It has been suggested that an intervention aiming these bacteria's starving could benefit the reduction of the inflammatory processes and be a part of AS treatment. The bowel microflora depends on dietary intake, like undigested starch, for their growth. Some studies have highlighted the relation between the intake of starch and the disease activity. The modulation of the microbiota, particularly, the reduction of Klebsiella, may be beneficial as a complementary approach to AS therapy.
A sample of 300 patients with AS, followed-up at Portuguese Institute of Rheumatology in Lisbon, will be randomly assigned in two groups. The group A will adopt a balanced diet based on the general recommendations for healthy eating by the World Health Organization, for a period of 6 weeks. In Group B will be implemented an individual balanced low starch diet, which is characterized by the significant reduction of starchy food, of at least 40% of the total daily ingested starch.
The change in biometric data, body composition, intestinal Klebsiella will be related to food intake, disease activity and quality of life assessments. These data will be compared between the 2 groups (diet A versus diet B), obtaining measures on the effect of each diet on the analyzed variables.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Effect of a Low Starch Diet in the Gut Microbiome Modulation, Disease Activity and Quality of Life in Patients With Ankylosing Spondylitis|
|Estimated Study Start Date :||July 1, 2020|
|Estimated Primary Completion Date :||May 30, 2021|
|Estimated Study Completion Date :||September 30, 2021|
Experimental: Low Starch Diet (LSD)
Participants will receive the low starch diet program: restricts the daily amount of ingested rich starch food, to a reduction of at least 40% compared to usual daily individual starch intake.
Behavioral: Low Starch Diet (LSD)
6-week balanced diet program, adapted to individual energetic needs, with significant reduction of high content starchy food, naturally present in plant cells, roots, tubers, seeds, beans, legumes, fruits, and highly present in most farinaceous grains, especially in potatoes, corn, rice, pasta, bread, cookies and cakes.
Active Comparator: Control
Participants will receive dietary counselling based on general recommendations for healthy eating.
Behavioral: General healthy eating
6-week balanced healthy eating counseling program, according to the World Health Organization recommendations.
- Change in intestinal Klebsiella [ Time Frame: 6 weeks (at baseline and the end of follow-up between the two groups) ]To compare the mean change of Klebsiella bacteria in faecal samples between the LSD group and the control.
- Change in mean erythrocyte sedimentation rate (ESR) [ Time Frame: 6 weeks (at baseline and the end of follow-up) ]Plasma concentrations will be assessed to evaluate ESR, a marker of systemic inflammation that provided insights into the overall anti-inflammatory effect of rheumatologic therapies. Data are presented as mean ESR value in millimeters per hour (mm/hr) ± standard deviation.
- Change in mean C-reactive protein (CRP) [ Time Frame: 6 weeks (at baseline and the end of follow-up) ]Plasma concentrations will be assessed to evaluate CRP, a marker of systemic inflammation that provided insights into the overall anti-inflammatory effect of rheumatologic therapies. Data are presented as mean CRP value in milligrams per liter (mg/L) ± standard deviation.
- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [ Time Frame: 6 weeks (at baseline and the end of follow-up) ]The BASDAI is a six question, participant-reported measure of overall disease activity that probed the level of fatigue, neck/back/hip pain, peripheral joint swelling and pain, localized tenderness, as well as morning stiffness severity and duration. The mean measurement (score) of questions 5 and 6 is added to the scores from questions 1 to 4 and divided by 5 to calculate the total BASDAI score. It is scored on a numerical rating scale that ranges from 0 (no symptoms) to 10 (severe symptoms), higher scores indicating severe disability due to AS disease. Data are presented as mean total BASDAI score +/- standard deviation.
- Bath Ankylosing Spondylitis Function Index (BASFI) [ Time Frame: 6 weeks (at baseline and the end of follow-up) ]The BASFI is a self-assessment instrument used to assess function. It comprises 8 specific questions regarding function in AS and 2 questions to identify participant's ability to cope up with everyday life. Each question is answered on a 100 millimeter (mm) horizontal VAS. The mean VAS score gives BASFI score between 0 to 100 where 0=easy to 100=impossible.
- Ankylosing Spondylitis Disease Activity Score (ASDAS) [ Time Frame: 6 weeks (at baseline and the end of follow-up) ]ASDAS includes CRP mg/L; four additional self-reported items (rated on 0-10cm VAS or 0-10 numerical rating scale [NRS]) included are total back pain (TBP), duration of morning stiffness (DMS), peripheral pain/swelling and patient global assessment (PGA). ASDAS scores calculated as: ASDAS(CRP) = (0.121*total back pain) + (0.110*participant global) + (0.073*peripheral pain/swelling) + (0.058* duration of morning stiffness) + (0.579*Ln(CRP+1). The disease activity, TBP, and peripheral pain/swelling on a numeric rating scale (from 0 (normal) to 10 (very severe)) and DMS on a numeric rating scale (0 to 10, with 0 being none and 10 representing a duration of =>2 hours). Inactive disease is defined as an ASDAS score <1.3.
- Bath Ankylosing Spondylitis Patient Global Score (BAS-G) [ Time Frame: 6 weeks (at baseline and the end of follow-up) ]The self-administered Bath Ankylosing Spondylitis Global (BAS-G) measures global consequences of axial spondyloarthritis, indicating the effect of disease on participant's well-being. This scale is composed of 2 items ranging from 0 = very good to 10 =very bad. Total score ranges from 0 to 10: the higher the BAS-G score, the worse the participant's health status.
- Ankylosing Spondylitis Quality of Life (ASQoL) [ Time Frame: 6 weeks (at baseline and the end of follow-up) ]The Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire is a disease-specific instrument designed to measure the health related quality of life (HRQOL) in participants with AS. Participants answer yes/no to 18 items assessing the current impact of AS on their quality of life status. The total score ranges from 0 to 18, with lower scores representing better AS-specific quality of life. Negative numbers indicate improvement from baseline.
- Euro Quality of Life-5D (EQ-5D) [ Time Frame: 6 weeks (at baseline, 2-weeks, 4-weeks, end of follow-up) ]The EQ-5D is a standardized, generic measure of health outcome, designed for self-completion by participants. The EQ-5D includes a descriptive section with 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that are combined into an overall health utilities index, and an NRS (100 mm VAS) that measures perception of overall health, with 0 indicating worst health and 100 representing best imaginable health.
- Change in Short Form (36) Health Survey (SF-36) [ Time Frame: 6 weeks (at baseline and the end of follow-up) ]SF-36 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales. The PCS had 4 subscales: physical function, role limitations due to physical problems, pain, and general health perception. The MCS had 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores indicate better health and well-being.
- Change in ASAS response criteria [ Time Frame: 6 weeks (at baseline and the end of follow-up) ]The Assessment in SpondyloArthritis international Society (ASAS) 20 response is defined as an improvement of >= 20% and absolute improvement of >= 1 unit (on a scale of 0 to 10) from Baseline in at least three of the following four domains, with no deterioration (where deterioration is defined as a worsening of >= 20% and a net worsening of >= 1 units [on a scale of 0 to 10]) in the remaining domains: Patient's Global Assessment, Pain, Function, Inflammation.
- Change in pain, fatigue and stiffness by patient's Visual analogue scale (VAS) [ Time Frame: 6 weeks (at baseline, 2-weeks, 4-weeks, end of follow-up) ]The VAS score assessed by participants, is used to determine the symptom (pain, fatigue and stiffness) impact due to AS in the past week. The level is measured in millimeters (mm) on a 100 mm horizontal line. The score ranges from 0 (no pain) to 100 (severe pain). Data are presented as mean VAS score +/- standard deviation.
- Individual evolution of intestinal Klebsiella [ Time Frame: 6 weeks (at baseline, 2-weeks, 4-weeks, end of follow-up) ]To compare the average change of Klebsiella bacteria, quantified in colony-forming unit per gram of feces (cfu/gr) in faecal samples among each participant.
- Change in Weight [ Time Frame: 6 weeks (at baseline and the end of follow-up) ]To compare the average change in weight (kilograms) between LSD group and the controls, before and after the intervention.
- Change in body mass index (BMI) [ Time Frame: 6 weeks (at baseline and the end of follow-up) ]To compare the average change in BMI (kg/m2), calculated by weight/(height^2), between LSD group and the controls, before and after the intervention.
- Change in body composition [ Time Frame: 6 weeks (at baseline and the end of follow-up) ]To compare the average change in percentage of the evaluation of the body fat mass between LSD group and the controls, before and after the intervention.
- Quantification of the average starch intake through 24h dietary recall [ Time Frame: 6 weeks (3 days of each week till the end of follow-up) ]To quantify the average starch dietetic content (in grams per day), determined through the 24h dietetic recall applied for 3 days, to calculate the ingested starch during the intervention and determine the respective individual percentage of average reduction.
- Quantification of average dietetic starch [ Time Frame: 5 days before baseline ]To quantify the usual individual daily dietetic intake of starch (grams per day), through the 24h dietary recall applied for 5 days.
- Identification and quantification of intestinal microbiota [ Time Frame: 6 weeks (at baseline and at the end of follow-up) ]To characterize the intestinal flora, namely, the presence of Klebsiella pneumoniae quantified in colony-forming unit per gram of feces (cfu/gr) in faecal samples.
- Determination of height [ Time Frame: at baseline ]To determine the height (meters) in all participants at baseline.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04386538
|Contact: Alexandra MT Cardoso, MDemail@example.com|
|Instituto Português de Reumatologia|
|Contact: Alexandra Cardoso, MD +351926142356 firstname.lastname@example.org|
|Principal Investigator: Alexandra Cardoso, MD|
|Sub-Investigator: Maria Leonor Silva, PhD|
|Sub-Investigator: Patrícia Padrão, PhD|
|Sub-Investigator: José Vaz Patto, Dr|
|Sub-Investigator: Maria Alexandra Bernardo, PhD|
|Sub-Investigator: Maria Fernanda Mesquita, PhD|
|Sub-Investigator: Pedro Moreira, PhD|
|Principal Investigator:||Alexandra MT Cardoso, MD||Universidade do Porto|
|Study Director:||Maria Leonor Silva, PhD||Centro de Investigação Interdisciplinar Egas Moniz|
|Study Director:||Patrícia Padrão, PhD||Universidade do Porto|